Despite a negative trajectory in incidence of cases worldwide, Gastric Cancer is still a commonly occurring disease that affects elderly patients more predominantly. A disproportionate number of identified cases are diagnosed in later disease stages of Gastric Cancer, which can rule out surgery as a treatment option, leaving less selective, systemic options which commonly involve chemotherapy, either as monotherapy or combined with other therapies. Chemotherapy is also commonly used as adjuvant therapy in cases treatable with surgical intervention or resection, radiotherapy, or targeted therapies.
Emphasis is needed in researching strategies of treatment that don’t rely on removing gastric tissues, as the lack of obvious diagnostic markers mean late identification can often rule out this intervention method. Chemotherapy is also prone to causing adverse effects in organs and tissues not targeted by the chemotherapeutic agent, and considerations such as the route of administration can impact the palatability of this treatment method. Further research is needed to identify new chemotherapeutic options, and to refine those already there for the benefit of the patient and their prognosis.
This Research Topic is intended to highlight some of the new refinements emerging with regard to chemotherapy treatment in Gastric Cancers, as well as the ways that researchers and clinicians are aiding gastric cancer patients undergoing chemotherapy by streamlining and supplementing their treatments, and by delivering these drug molecules via tailored routes.
We welcome Original Research, leading-edge Reviews and Clinical Trials related but not limited to the aspects below:
-Different routes of chemotherapy administration and their efficacy
-Use of chemotherapy pre/post-operatively
-Chemotherapeutic adjuvant/neoadjuvant therapies
- Mechanisms of refining chemotherapy treatment or minimizing adverse effects
- Secondary supplementation in gastric cancer patients
- Maintenance chemotherapy for patients with advanced or metastatic gastric cancer;
- Metronomic chemotherapy for gastric cancer;
- Novel indicators for efficacy and safety in gastric cancer patients receiving chemotherapy;
- Chemotherapy for gastric signet ring cell carcinoma;
- Use of digital mobile medicine interventions (e.g., APP) to improve treatment compliance and case surveillance in patients with gastric cancer undergoing chemotherapy
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Despite a negative trajectory in incidence of cases worldwide, Gastric Cancer is still a commonly occurring disease that affects elderly patients more predominantly. A disproportionate number of identified cases are diagnosed in later disease stages of Gastric Cancer, which can rule out surgery as a treatment option, leaving less selective, systemic options which commonly involve chemotherapy, either as monotherapy or combined with other therapies. Chemotherapy is also commonly used as adjuvant therapy in cases treatable with surgical intervention or resection, radiotherapy, or targeted therapies.
Emphasis is needed in researching strategies of treatment that don’t rely on removing gastric tissues, as the lack of obvious diagnostic markers mean late identification can often rule out this intervention method. Chemotherapy is also prone to causing adverse effects in organs and tissues not targeted by the chemotherapeutic agent, and considerations such as the route of administration can impact the palatability of this treatment method. Further research is needed to identify new chemotherapeutic options, and to refine those already there for the benefit of the patient and their prognosis.
This Research Topic is intended to highlight some of the new refinements emerging with regard to chemotherapy treatment in Gastric Cancers, as well as the ways that researchers and clinicians are aiding gastric cancer patients undergoing chemotherapy by streamlining and supplementing their treatments, and by delivering these drug molecules via tailored routes.
We welcome Original Research, leading-edge Reviews and Clinical Trials related but not limited to the aspects below:
-Different routes of chemotherapy administration and their efficacy
-Use of chemotherapy pre/post-operatively
-Chemotherapeutic adjuvant/neoadjuvant therapies
- Mechanisms of refining chemotherapy treatment or minimizing adverse effects
- Secondary supplementation in gastric cancer patients
- Maintenance chemotherapy for patients with advanced or metastatic gastric cancer;
- Metronomic chemotherapy for gastric cancer;
- Novel indicators for efficacy and safety in gastric cancer patients receiving chemotherapy;
- Chemotherapy for gastric signet ring cell carcinoma;
- Use of digital mobile medicine interventions (e.g., APP) to improve treatment compliance and case surveillance in patients with gastric cancer undergoing chemotherapy
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
